EWTX · NASDAQ
Edgewise Therapeutics (EWTX) Stock Price & Fundamentals
Edgewise Therapeutics (EWTX) closed at $530.69 on Oct 9, 2026, up 0.34% from the previous close of $528.87.
Share price, past year
1Y +23.32%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $530.69 |
| Sep 30, 2026 | $532.44 |
| Aug 31, 2026 | $520.60 |
| Jul 31, 2026 | $510.40 |
| Jun 30, 2026 | $519.85 |
| May 29, 2026 | $494.96 |
| Apr 30, 2026 | $513.11 |
| Mar 31, 2026 | $521.81 |
| Feb 27, 2026 | $537.18 |
| Jan 30, 2026 | $515.42 |
| Dec 31, 2025 | $507.43 |
| Nov 28, 2025 | $479.36 |
| Oct 31, 2025 | $464.40 |
Key statistics
- Market cap
- $57.20B
- EPS (TTM)
- −$1.85
- Net income (TTM)
- −$197.22M
- Shares outstanding
- 107.8M
- 52-week range
- $428.97 – $545.17
Edgewise Therapeutics's market cap is $57.20B, based on a share price of $530.69 and 107.8M shares outstanding as of Jun 30, 2026.
Financials
Edgewise Therapeutics's SEC filings don't report revenue in the standard form Laurel reads, so its revenue history isn't shown yet.
Edgewise Therapeutics reported a net loss of $167.80M in fiscal 2025.
Company profile
- Name
- Edgewise Therapeutics, Inc.
- Ticker
- EWTX
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 1715 38th St, Boulder, CO 80301
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001710072
Recent SEC filings
- Aug 6, 2026
- Aug 6, 2026
- Jul 13, 2026
- Jun 5, 2026
- Jun 1, 2026
- May 7, 2026
- May 7, 2026
- Feb 26, 2026
Frequently asked questions
What is Edgewise Therapeutics's stock price?
Edgewise Therapeutics (EWTX) closed at $530.69 on Oct 9, 2026, up 0.34% from the previous close of $528.87.
What is Edgewise Therapeutics's market cap?
Edgewise Therapeutics's market cap is $57.20B, based on a share price of $530.69 and 107.8M shares outstanding as of Jun 30, 2026.
Does Edgewise Therapeutics pay a dividend?
Edgewise Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Edgewise Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures